SETD2 and nonpapillary renal cell carcinoma: Moreover, using custom epithelial and mesenchymal gene signatures derived from published gene sets [13], we observe that a mesenchymal gene signature is enriched in SETD2 KO, TGF‐β‐treated WT, and SETD2‐mutant ccRCC samples, while an epithelial expression signature is depleted (Fig. 1H).